Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Illumina Inc (ILMN)

Illumina Inc (ILMN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 21,998,618
  • Shares Outstanding, K 152,800
  • Annual Sales, $ 4,372 M
  • Annual Income, $ -1,223 M
  • EBIT $ 782 M
  • EBITDA $ 1,136 M
  • 60-Month Beta 1.41
  • Price/Sales 5.34
  • Price/Cash Flow 31.33
  • Price/Book 9.43

Options Overview Details

View History
  • Implied Volatility 48.09% (+1.57%)
  • Historical Volatility 33.45%
  • IV Percentile 65%
  • IV Rank 27.24%
  • IV High 84.13% on 04/08/25
  • IV Low 34.59% on 11/14/25
  • Expected Move (DTE 35) 14.79 (10.18%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 703
  • Volume Avg (30-Day) 1,471
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 53,617
  • Open Int (30-Day) 55,697
  • Expected Range 130.51 to 160.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.20
  • Number of Estimates 1
  • High Estimate 1.20
  • Low Estimate 1.20
  • Prior Year 0.86
  • Growth Rate Est. (year over year) +39.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
129.29 +12.38%
on 12/17/25
151.34 -3.99%
on 01/07/26
+10.38 (+7.69%)
since 12/15/25
3-Month
93.50 +55.40%
on 10/16/25
151.34 -3.99%
on 01/07/26
+52.30 (+56.24%)
since 10/15/25
52-Week
68.70 +111.50%
on 04/09/25
151.34 -3.99%
on 01/07/26
+9.11 (+6.69%)
since 01/15/25

Most Recent Stories

More News
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery

The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale

ILMN : 145.30 (+0.92%)
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025

SAN DIEGO , Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year...

ILMN : 145.30 (+0.92%)
Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026

SAN DIEGO , Jan. 12, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on Thursday,...

ILMN : 145.30 (+0.92%)
Illumina Appoints Dr. Eric Green as Chief Medical Officer

Veteran genomics leader joins Illumina to advance global medical strategy Illumina chief commercial officer to depart for role as a life science tools company CEO 

ILMN : 145.30 (+0.92%)
Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025

DGX : 190.26 (+1.87%)
EXAS : 102.34 (+0.08%)
ILMN : 145.30 (+0.92%)
ARVN : 12.13 (-0.57%)
PFE : 25.89 (+1.21%)
QTRX : 7.95 (+8.16%)
Illumina launches powerful software for connected, intuitive, and scalable multiomic analysis

Integrated software, AI-driven analytics, and frictionless workflows enable customers to harness the full power of biological insights

ILMN : 145.30 (+0.92%)
1 Profitable Stock to Own for Decades and 2 Facing Challenges

1 Profitable Stock to Own for Decades and 2 Facing Challenges

AMSC : 31.08 (-0.54%)
ILMN : 145.30 (+0.92%)
MLM : 640.94 (+0.66%)
Illumina To Webcast Upcoming Investor Conference

SAN DIEGO , Dec. 16, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that members of its management team will participate at the following investor conference:

ILMN : 145.30 (+0.92%)
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention.

ILMN : 145.30 (+0.92%)
The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

The Ensign Group, Illumina, and Amphastar Pharmaceuticals Shares Skyrocket, What You Need To Know

ILMN : 145.30 (+0.92%)
AMPH : 26.00 (-6.34%)
ENSG : 183.54 (+3.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Illumina Inc. is a life sciences company, which provides tools and integrated systems for analysis of genetic variation and function. Using its proprietary technologies, the company provides innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies,...

See More

Key Turning Points

3rd Resistance Point 151.17
2nd Resistance Point 148.99
1st Resistance Point 147.15
Last Price 145.30
1st Support Level 143.13
2nd Support Level 140.95
3rd Support Level 139.11

See More

52-Week High 151.34
Last Price 145.30
Fibonacci 61.8% 119.77
Fibonacci 50% 110.02
Fibonacci 38.2% 100.27
52-Week Low 68.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar